Flux Robotics announces the successful closing of its pre-seed round, supported by Future Tech Ventures and NextGen Ventures. This investment is further complemented by public support through a Health~Holland PPP subsidy, facilitated via our collaboration with the University Medical Center Groningen (UMCG).
The new funding marks a major milestone in our journey to bring safe, precise, and efficient vascular interventions to patients suffering from chronic total occlusions (CTOs). By combining robotic precision with magnetic navigation, we aim to overcome some of the most difficult challenges in peripheral artery disease.
Related: Dilon Technologies closes $9m in Growth Capital Financing
This pre-seed support accelerates our next critical milestones:
- Completion of pre-clinical trials
- Product refinements to the Flux 2 navigation system and Uniflux crossing wire
- Strategic growth of our engineering and clinical teams
As part of our ongoing growth, we are establishing a local presence in Groningen, deepening ties with clinical and academic partners in the region. This step reinforces our commitment to contribute to the Dutch MedTech ecosystem and strengthen our national footprint alongside our roots in Twente.
Christoff Heunis, CEO of Flux Robotics: “This investment helps us move faster toward clinical validation, expand our technical capabilities, and strengthen our partnerships across Europe and beyond. We’re excited to keep building with the support of investors who believe in the future of magnetic robotics. It is also a key enabler as we venture north to establish our clinical hub in Groningen, bringing us closer to patients, surgeons, and the frontline of innovation.”
